NCT06503211View on ClinicalTrials.gov

On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions
Recurrent or Refractory B-cell Non Hodgkin's Lymphoma
Interventions
BIOLOGICAL

UTAA09 injection

The subjects, who sign the informed consent forms and been screeneinclusion/exclusion criteria, will be assigned into 3 x 108\~1 x 1010 CD19-CAR - γδT cells.

Trial Locations (1)

230088

RECRUITING

PersonGen.Anke Cellular Therapeutice Co., Ltd., Hefei

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER